Muva nje, uNantong Chanyoo wenze enye ingqopha-mlando emlandweni! Ngemizamo engaphezu konyaka owodwa, i-KDMF yokuqala ye-Chanyoo ivunyelwe yi-MFDS. Njengomkhiqizi omkhulu weRosuvastatin Calcium eChina,sifisa ukuvula isahluko esisha emakethe yaseKorea.Futhi imikhiqizo eminingi izokwethulwa eminyakeni embalwa ezayo.

Futhi, ungabheka futhi uthole imininingwane yethu kule webhusayithi:

https://nedrug.mfds.go.kr/pbp/CCBAC03

I-Rosuvastatin calcium ilungele ukwelashwa kwe-adjuvant ezigulini ezine-hypercholesterolemia eyinhloko (uhlobo IIa, okuhlanganisa i-heterozygous family hypercholesterolemia) noma i-mixed lipemia (uhlobo IIb) lapho ukudla noma ukuzivocavoca umzimba kungafanele.I-Rosuvastatin calciumiyi-3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor ekhethiwe. Ngokuvimbela i-HMG-CoA reductase, inciphisa ukuhlanganiswa kwamaseli esibindi nokugcinwa kwe-cholesterol, ngaleyo ndlela Yehlisa i-cholesterol ephelele yegazi (TC) kanye namazinga e-low-density lipoprotein cholesterol (LDL-C).

Ngokusho kwedatha ye-Newport, kusukela ngoJuni 30, 2018 kuya kuJuni 30, 2019, ukuthengiswa komhlaba wonke kwamalungiselelo e-rosuvastatin calcium bekungama-US$3.461 billion, ukwehla konyaka ngonyaka ngo-13%; ukuthengiswa komhlaba wonke kwezinto zokusetshenziswa kwe-calcium ye-rosuvastatin bekungamathani ayi-151.09, Ukukhuphuka konyaka ngo-14%

Thina,I-Changzhou Pharmaceutical Factory(umkhiqizi osizayo: i-Nantong Chanyoo Pharmatech Co., Ltd.) sizinikele kumnikezeli omkhulu we-Rosuvastatin API.